Osimertinib plus chemotherapy versus osimertinib for patients with advanced NSCLC with concomitant EGFR and TP53 mutations: a prospective cohort study

Abstract Osimertinib is the standard first-line options for patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC). Co-mutations in TP53 results in poor survival for patients. However, the studies on treatment options and clinical outcomes of patients with EGFR-TP53 co- mutation are...

Full description

Bibliographic Details

Published in:	Scientific Reports
Main Authors:	Jixian Li, Xiang Zhan, Mengqing Shao, Renya Zeng, Jianan Li, Hui Zhu, Alei Feng, Zhe Yang, Wang Jing
Format:	Article
Language:	English
Published:	Nature Portfolio 2025-07-01
Subjects:	NSCLC Osimertinib EGFR TP53 Chemotherapy
Online Access:	https://doi.org/10.1038/s41598-025-03422-9